Chemspace | substituted pyrazine derivatives

Warning!
Your browser does not support JavaScript or JavaScript support is disabled.
Display of the content may be incorrect. Please make sure that JavaScript is enabled in your browser. Warning!
Apparently you are using proxy server to access this site.
It means that display of the content may be incorrect.

Warning!
Your browser does not support HTML5.
Display of the content may be incorrect. Please make sure that your browser supports HTML5 syntax.

Home News Favipiravir (Avigan) analogs

24 March 2020

Favipiravir (Avigan) analogs

Favipiravir (Avigan) was approved in Japan in 2014 for treating viral strains unresponsive to current antivirals. It is a substituted pyrazine derivative that inhibits the replication of many RNA viruses. Now FDA completed Phase 3 clinical trial studying safety and efficacy of it for the treatment of uncomplicated influenza. And Favipiravir seemed to be effective in treating COVID-19. We have created a set of Building Blocks, which are similar to this molecule, to generate new ideas for your projects:

Favipiravir (Avigan) analogs

Enquire for x () from in

Enquire for

Would you like to submit a custom request?

Enquiry for a list of compounds

Please select the ship to country:

Sign in